Healthcare Services

Atopic Dermatitis Market Expected To Witness Revenue Growth Toward $19.53 Billion By 2030

May 27, 2026June 3, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Will The Market Value Of The Atopic Dermatitis Market Change Between 2026 And 2030?

The atopic dermatitis market has seen substantial growth in its size over recent years. Projections indicate it will expand from $9.88 billion in 2025 to $11.34 billion in 2026, achieving a compound annual growth rate (CAGR) of 14.8%. Historically, this expansion has been driven by factors such as the increasing prevalence of chronic skin conditions, the wider availability of topical corticosteroids, the expansion of dermatology care services, growing awareness of eczema management, and improved diagnostic accuracy.

The atopic dermatitis market size is expected to show substantial growth over the next few years, projected to reach $19.53 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 14.6%. This expansion during the forecast period is driven by factors such as the increasing adoption of biologics and JAK inhibitors, a heightened focus on personalized dermatology treatments, the broadening of injectable therapy options, rising investment in dermatology research, and a growing demand for long-term symptom control. Significant trends for the forecast period include the increasing uptake of biologic therapies, an elevated demand for targeted immunomodulators, an intensified focus on long-term disease management, the expansion of advanced topical formulations, and an enhanced emphasis on patient-centric treatment approaches.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8285&type=smp

What Core Drivers Are Transforming The Atopic Dermatitis Market?

The rising need for personalized medicine is anticipated to boost the atopic dermatitis market in the coming years. Personalized medicine signifies a novel approach to healthcare and medical treatment, adapting medical choices, practices, interventions, and drug regimens to suit each individual patient. In the context of atopic dermatitis, personalized medicine entails pinpointing specific genetic and molecular elements that influence the condition, facilitating the creation of targeted therapies that cater to the distinct attributes of every patient. This methodology not only improves the effectiveness of treatment but also reduces unwanted side effects. As an example, the Personalized Medicine Coalition, a US-based advocacy organization for customized medical therapies, reported in February 2024 that the FDA cleared 16 new personalized treatments for individuals with rare diseases in 2023, an increase from six in 2022. Consequently, the growing demand for personalized medicine is fueling the expansion of the atopic dermatitis market.

How Is The Atopic Dermatitis Market Examined Through Segment Analysis?

The atopic dermatitis market covered in this report is segmented –

1) By Drug Class: Corticosteroids, Emollients Or Moisturizers, IL-4 And PDE4 Inhibitors, Calcineurin Inhibitors, Other Drug Classes

2) By Mode of Administration: Topical, Injectable, Oral

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Corticosteroids: Topical Corticosteroids, Systemic Corticosteroids

2) By Emollients Or Moisturizers: Creams and Lotions, Ointments and Balms, Barrier Repair Creams

3) By IL-4 And PDE4 Inhibitors: Dupilumab (IL-4 Inhibitor), Apremilast (PDE4 Inhibitor)

4) By Calcineurin Inhibitors: Tacrolimus Ointment, Pimecrolimus Cream

5) By Other Drug Classes: Biologics, JAK Inhibitors

Which Trends Are Expected To Shape The Atopic Dermatitis Market?

Major companies within the atopic dermatitis market are concentrating on developing innovative treatments, such as IL-31 receptor antagonists, with the goal of addressing persistent itching, improving the management of skin symptoms, and reducing systemic side effects compared to traditional corticosteroids or immunosuppressants. An IL-31 receptor antagonist operates by impeding the IL-31 signaling pathway, which is directly implicated in both itch sensation and inflammation, providing a more targeted method than widespread immune suppression. For instance, in December 2024, Galderma, a dermatology firm based in Switzerland, obtained FDA approval for Nemluvio (nemolizumab), marking it as the inaugural monoclonal antibody specifically designed to target the IL-31 receptor alpha to block IL-31 signaling in moderate-to-severe atopic dermatitis. This therapy is given through subcutaneous injection, where it binds to the IL-31 receptor to prevent its activation by the IL-31 cytokine, and clinical studies have indicated its effectiveness in delivering rapid itch relief and significant betterment in skin symptoms when used in conjunction with topical treatments.

Which Organizations Are Operating Within The Atopic Dermatitis Market?

Major companies operating in the atopic dermatitis market are Sanofi SA, Regeneron Pharmaceuticals Inc., Novartis International AG, Pfizer Inc., AbbVie Inc., Astellas Pharma Inc., Arcutis Biotherapeutics Inc., Asana Biosciences LLC, Dermavant Sciences Inc., Eli Lilly and Company, Galderma SA, Incyte Corporation, Bayer AG, Bausch Health Companies Inc., GlaxoSmithKline PLC, LEO Pharma A/S, Teva Pharmaceutical Industries Ltd., Allergan PLC, Menlo Therapeutics Inc., Johnson & Johnson, Merck & Co Inc., Amgen Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, Eisai Co. Ltd., Kyowa Kirin Co. Ltd., Mallinckrodt Pharmaceuticals Limited

Access The Complete Atopic Dermatitis Market Report:

https://www.thebusinessresearchcompany.com/report/atopic-dermatitis-global-market-report

Which Region Stands As The Largest Contributor To The Atopic Dermatitis Market?

North America was the largest region in the atopic dermatitis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the atopic dermatitis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Atopic Dermatitis Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=8285&type=smp

Browse Through More Reports Similar to the Global Atopic Dermatitis Market 2026, By The Business Research Company

Plastic Pipes And Pipe Fittings Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/plastic-pipes-and-pipe-fittings-global-market-report

Hot Dip Galvanizing Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/hot-dip-galvanizing-global-market-report

Drill Pipe Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/drill-pipe-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795